132 related articles for article (PubMed ID: 15307009)
1. Longitudinal effect of antiretroviral therapy on markers of hepatic toxicity: impact of hepatitis C coinfection.
French AL; Benning L; Anastos K; Augenbraun M; Nowicki M; Sathasivam K; Terrault NA
Clin Infect Dis; 2004 Aug; 39(3):402-10. PubMed ID: 15307009
[TBL] [Abstract][Full Text] [Related]
2. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.
Aranzabal L; Casado JL; Moya J; Quereda C; Diz S; Moreno A; Moreno L; Antela A; Perez-Elias MJ; Dronda F; Marín A; Hernandez-Ranz F; Moreno A; Moreno S
Clin Infect Dis; 2005 Feb; 40(4):588-93. PubMed ID: 15712082
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy.
Núñez M; Lana R; Mendoza JL; Martín-Carbonero L; Soriano V
J Acquir Immune Defic Syndr; 2001 Aug; 27(5):426-31. PubMed ID: 11511818
[TBL] [Abstract][Full Text] [Related]
4. Liver enzymes elevation after HAART in HIV-HCV co-infection.
Servin-Abad L; Molina E; Baracco G; Arosemena L; Regev A; Jeffers L; Schiff E
J Viral Hepat; 2005 Jul; 12(4):429-34. PubMed ID: 15985015
[TBL] [Abstract][Full Text] [Related]
5. HIV and hepatitis C virus co-infection.
Sulkowski M
Hopkins HIV Rep; 1998 Nov; 10(6):8, 12. PubMed ID: 11366132
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection.
den Brinker M; Wit FW; Wertheim-van Dillen PM; Jurriaans S; Weel J; van Leeuwen R; Pakker NG; Reiss P; Danner SA; Weverling GJ; Lange JM
AIDS; 2000 Dec; 14(18):2895-902. PubMed ID: 11153671
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral therapy-related hepatotoxicity: predictors and clinical management.
Dore G
J HIV Ther; 2003 Nov; 8(4):96-100. PubMed ID: 14671507
[TBL] [Abstract][Full Text] [Related]
8. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
[TBL] [Abstract][Full Text] [Related]
9. Liver toxicity and risk of discontinuation in HIV/hepatitis C virus-coinfected patients receiving an etravirine-containing antiretroviral regimen: influence of liver fibrosis.
Casado JL; Mena A; Bañón S; Castro A; Quereda C; Moreno A; Pedreira J; Moreno S
HIV Med; 2016 Jan; 17(1):62-7. PubMed ID: 26122981
[TBL] [Abstract][Full Text] [Related]
10. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort.
Torti C; Lapadula G; Casari S; Puoti M; Nelson M; Quiros-Roldan E; Bella D; Pastore G; Ladisa N; Minoli L; Sotgiu G; Mazzotta F; Lo Caputo S; Di Perri G; Filice G; Tinelli C; Carosi G;
BMC Infect Dis; 2005 Jul; 5():58. PubMed ID: 16018804
[TBL] [Abstract][Full Text] [Related]
11. Severe transaminitis after interferon-ribavirin therapy in HIV/HCV-coinfected patients: influence of a sustained HCV response.
Bani-Sadr F; Krastinova E; Fromentin D; Piroth L; Rosenthal E; Quertainmont Y; Perronne C; Cacoub P; Pol S; Carrat F;
J Viral Hepat; 2012 Jun; 19(6):431-5. PubMed ID: 22571905
[TBL] [Abstract][Full Text] [Related]
12. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study.
Carrieri MP; Lions C; Sogni P; Winnock M; Roux P; Mora M; Bonnard P; Salmon D; Dabis F; Spire B;
J Hepatol; 2014 Jan; 60(1):46-53. PubMed ID: 23978720
[TBL] [Abstract][Full Text] [Related]
13. Liver enzyme elevation in hepatitis C virus (HCV)-HIV-coinfected patients prior to and after initiating HAART: role of HCV genotypes.
Maida I; Babudieri S; Selva C; D'Offizi G; Fenu L; Solinas G; Narciso P; Mura MS; Núñez M
AIDS Res Hum Retroviruses; 2006 Feb; 22(2):139-43. PubMed ID: 16478395
[TBL] [Abstract][Full Text] [Related]
14. Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis C coinfection: data from the ICONA foundation cohort.
Di Biagio A; Nicolini LA; Lorenzini P; Puoti M; Antinori A; Cozzi-Lepri A; Gori A; Vecchiet J; Mussini C; Andreoni M; Viscoli C; d'Arminio Monforte A; For The Icona Foundation Study Group
HIV Clin Trials; 2014; 15(4):151-60. PubMed ID: 25143024
[TBL] [Abstract][Full Text] [Related]
15. Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.
Manfredi R; Calza L; Chiodo F
HIV Clin Trials; 2005; 6(6):302-11. PubMed ID: 16452064
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation of APRI score in liver disease following the introduction of antiretroviral therapy in HIV and HCV coinfected versus HIV monoinfected patients].
Antonello VS; Tovo CV; Kliemann DA; Santos BR; Zaltron VF
Rev Soc Bras Med Trop; 2010; 43(6):678-81. PubMed ID: 21181022
[TBL] [Abstract][Full Text] [Related]
17. Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders?
Gavazzi G; Bouchard O; Leclercq P; Morel-Baccard C; Bosseray A; Dutertre N; Micoud M; Morand P
AIDS Res Hum Retroviruses; 2000 Jul; 16(11):1021-3. PubMed ID: 10933615
[TBL] [Abstract][Full Text] [Related]
18. Liver injury during highly active antiretroviral therapy: the effect of hepatitis C coinfection.
Bonacini M
Clin Infect Dis; 2004 Mar; 38 Suppl 2():S104-8. PubMed ID: 14986282
[TBL] [Abstract][Full Text] [Related]
19. [Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV].
Gavazzi G; Richallet G; Morand P; Bouchard O; Bosseray A; Leclercq P; Micoud M
Pathol Biol (Paris); 1998 Jun; 46(6):412-5. PubMed ID: 9769871
[TBL] [Abstract][Full Text] [Related]
20. Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors.
Palmon R; Koo BC; Shoultz DA; Dieterich DT
J Acquir Immune Defic Syndr; 2002 Apr; 29(4):340-5. PubMed ID: 11917237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
